Ozmosi | Vinpocetine Drug Profile

Product Description

Mechanisms of Action: PDE Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Amen Clinics
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Stroke|Inflammation|Kidney Diseases|Diabetic Nephropathy

Phase 2: Epilepsy

Phase 1: Fetal Alcohol Spectrum Disorders

Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
IRB00044949	P2	Suspended	Epilepsy	2026-12-01	2024-08-17	Primary Endpoints
Protocol: 77615	P1	Not yet recruiting	Fetal Alcohol Spectrum Disorders	2026-06-01	2024-10-11	Primary Endpoints\|Treatments
NCT06441591	P3	Recruiting	Kidney Diseases\|Diabetic Nephropathy	2025-06-01	2024-06-05	Primary Endpoints
ChiCTR-IOR-14005688	N/A	Not yet recruiting	Unknown	2018-12-31
TianjinMUGH1	P3	Completed	Inflammation\|Stroke	2015-12-01	2019-03-20	Treatments
ISCAN 001	N/A	Completed	Traumatic Brain Injury	2010-06-01	2019-03-19	Treatments
CTR20191732	N/A	Not yet recruiting	Arteriosclerosis\|Cerebral Hemorrhage\|Ischemic Stroke	None	2025-04-29

Recent News Events

Date	Type	Title
06/11/2025	News Article	Oral Iron Supplements Market to Reach USD 4,128.06 Million by 2032, Driven by Rising Prevalence of Iron Deficiency Anemia - Credence Research
07/23/2024	News Article	Global Cardiovascular Health Supplements Market worth $16.06 billion by 2030, Exclusive Report by Coherent Market Insights
07/22/2024	News Article	Dyslexia Treatment Market Size to hit $11.74 billion by 2031, growing at a CAGR of 6.4%, says Coherent Market Insights
07/09/2024	News Article	Global Workout Supplements Market Size to worth $36.38 billion by 2030, growing at a CAGR of 10.9%, says Coherent Market Insights
05/13/2024	PubMed	The ameliorative effect of vinpocetine against gentamicin-induced uterine-injury in rats involves the inflammasome/caspase-1/IL-1beta pathway.
05/11/2024	PubMed	Regulation of cerebral blood flow boosts precise brain targeting of vinpocetine-derived ionizable-lipidoid nanoparticles.
04/09/2024	PubMed	Symptomatic Cavum Vergae Cyst in a Geriatric Patient: A Report of a Rare Case and Conservative Management Approach.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Vinpocetine

Alternative Names: vinpocetine, vinpocetin Clinical Status: Inactive Latest Update: 2024-10-10 Latest Update Note: Clinical Trial Update